指南与共识神经MRCT

2021年世界卫生组织中枢神经系统肿瘤分类的主要变化

Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.
PubMed 文献 · Radiographics · 2022-07-08

2021年世界卫生组织发布了第五版中枢神经系统肿瘤分类(WHO CNS5),基于cIMPACT-NOW建议修订,强调遗传和分子改变在肿瘤特征中的重要性。作者描述了WHO CNS5引入的主要变化,包括肿瘤命名修订、新识别的肿瘤类型及其分子机制、临床特征和影像学特点,指出放射科医生需熟悉这一新分类系统。

要点

  • 第四版WHO IV级肿瘤等同于第五版CNS WHO 4级肿瘤,弥漫性中线胶质瘤H3 K27M突变型等同于中线胶质瘤H3 K27改变型。
  • IDH突变型胶质母细胞瘤修改为IDH突变型星形细胞瘤,IDH突变型星形细胞瘤现根据CDKN2A/B纯合性缺失的有无进行分级。
  • WHO CNS5详述了多个新识别的肿瘤类型,包括神经影像学特征知识有限的类型。

核心结论

  • WHO CNS5基于cIMPACT-NOW建议制定,强调遗传和分子改变在中枢神经系统肿瘤特征中的重要性,成为日常实践的基础,放射科医生需熟悉这一新版分类系统。

研究设计与样本

  • 指南类文件,由世界卫生组织发布,基于cIMPACT-NOW建议制定,对2016年WHO中枢神经系统分类系统进行更新。

诊断标准与关键数值

  • 第四版WHO IV级肿瘤等同于第五版CNS WHO 4级肿瘤。
  • 弥漫性中线胶质瘤H3 K27M突变型等同于中线胶质瘤H3 K27改变型。
  • IDH突变型胶质母细胞瘤修改为IDH突变型星形细胞瘤。
  • IDH突变型星形细胞瘤根据CDKN2A/B纯合性缺失的有无进行分级。

局限性

  • WHO CNS5详述的多个新识别肿瘤类型中,部分类型的神经影像学特征知识有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The World Health Organization (WHO) published the fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5) in 2021, as an update of the WHO central nervous system (CNS) classification system published in 2016. WHO CNS5 was drafted on the basis of recommendations from the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) and expounds the classification scheme of the previous edition, which emphasized the importance of genetic and molecular changes in the characteristics of CNS tumors. Multiple newly recognized tumor types, including those for which there is limited knowledge regarding neuroimaging features, are detailed in WHO CNS5. The authors describe the major changes introduced in WHO CNS5, including revisions to tumor nomenclature. For example, WHO grade IV tumors in the fourth edition are equivalent to CNS WHO grade 4 tumors in the fifth edition, and diffuse midline glioma, H3 K27M-mutant, is equivalent to midline glioma, H3 K27-altered. With regard to tumor typing, isocitrate dehydrogenase (IDH)-mutant glioblastoma has been modified to IDH-mutant astrocytoma. In tumor grading, IDH-mutant astrocytomas are now graded according to the presence or absence of homozygous CDKN2A/B deletion. Moreover, the molecular mechanisms of tumorigenesis, as well as the clinical characteristics and imaging features of the tumor types newly recognized in WHO CNS5, are summarized. Given that WHO CNS5 has become the foundation for daily practice, radiologists need to be familiar with this new edition of the WHO CNS tumor classification system. Online supplemental material and the slide presentation from the RSNA Annual Meeting are available for this article. ©RSNA, 2022.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Kurokawa, Kurokawa, Baba, et al. Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors. Radiographics. 2022. PMID: 35802502. doi:10.1148/rg.210236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。